John Thompson named director Consortium's phase I trials

Dr. John Thompson
Dr. John Thompson Clinical Research Division

Dr. John Thompson recently took the helm of the new phase I clinical trials program for solid-tumor cancers for the Fred Hutchinson/University of Washington Cancer Consortium. Thompson, part of the Clinical Research Division, has served as medical director of the Seattle Cancer Care Alliance's general oncology service since 2001 and co-directs the Melanoma Clinic.

Thompson's new role involves developing new early phase clinical trials, either industry or investigator initiated; helping to coordinate the infrastructure needed for such studies, including research nurses, data coordinators, regulatory affairs, tissue acquisition and biostatistical support; working with medical oncology and other faculty to assure patient accrual to studies; and direct care of a portion of the study patients.

"John has a demonstrated track record in these areas," said Dr. Mac Cheever, director of the Center's Solid Tumor Research program.

Phase I trials determine whether and how a drug works. Traditionally, such studies have been primarily concerned with drug safety. However, with the increased knowledge of the molecular pathways involved in cancer development, an ever-increasing proportion of drugs tested in humans prove to be effective, even in the first patients treated. The phase I program will also support the research programs of local biotech and pharmaceutical companies as well as Consortium translational researchers.

Help Us Eliminate Cancer

Every dollar counts. Please support lifesaving research today.